Browse News
Filter News
Found 12 articles
-
Biotia, Pioneering Pathogen Detection Company, Raises an Oversubscribed $8M Series A
8/23/2022
New York, NY -- August 23, 2022 -- Biotia, a company fighting infectious diseases powered by genomics and artificial intelligence (AI), has raised an oversubscribed $8 million Series A round led by OCA Ventures.
-
Biotia Selected By Mayo Clinic Platform To Accelerate The Success of Its AI Diagnostic Software
8/15/2022
Mayo Clinic Platform, a strategic initiative to improve health care through insights and knowledge derived from data, has selected Biotia, a company fighting infectious diseases powered through genomics and artificial intelligence (AI), to join its Accelerate program with a focus on model validation and clinical readiness.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
Twist Bioscience Reports Fiscal Third Quarter 2022 Financial Results
8/5/2022
Twist Bioscience Corporation today reported financial results and business highlights for the third quarter of fiscal 2022 ended June 30, 2022.
-
Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2
8/2/2022
Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2.
-
Biotia's Newest Software for SARS-CoV-2 Genetic Surveillance Sees Rapid Adoption By Researchers Seeking Deeper Insights
9/8/2021
Biotia, Inc., a company that delivers proprietary analytical software for infectious disease diagnostics, is experiencing rapid adoption by clinical researchers worldwide of its user-friendly software platform for the comprehensive surveillance and deeper insights into COVID-19 viral genetic variants.
-
Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
5/6/2021
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2021 ended March 31, 2021.
-
Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay
3/24/2021
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay.
-
The new state-of-the-art facility, dubbed the “Factory of the Future,” will span 110,000 square feet and will be located in the city of Wilsonville, Oregon.
-
Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
11/19/2020
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.
-
Highlights: NanoVapor Biotech forms Executive Advisory team to address pandemic mitigation
5/19/2020
Today, NanoVapor Biotech, a division of NanoVapor Inc., announces a newly formed Executive Advisory team to address innovation in pandemic mitigation using nanotechnology on an industrial scale.
-
Biotia, Pioneering Pathogen Detection Company, Raises $2.4M Seed Round, Expands Scientific Advisory Board
12/10/2019
Biotia, a health tech company leveraging next-generation DNA sequencing (NGS) and artificial intelligence (AI) software for precision infectious disease detection and diagnosis, today announced an oversubscribed $2.4M seed raise and expanded scientific advisory board .